We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+13.53%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$652M
AUM Growth
+$113M
Cap. Flow
+$93.9M
Cap. Flow %
14.4%
Top 10 Hldgs %
48.49%
Holding
247
New
47
Increased
63
Reduced
54
Closed
37

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$52.7M
2
PRTA icon
Prothena Corp
PRTA
+$25.3M
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$13M
4
CYTK icon
Cytokinetics
CYTK
+$6.66M
5
SVRA icon
Savara
SVRA
+$6.09M

Top Sells

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$16.7M
2
SWTX
SpringWorks Therapeutics
SWTX
+$8.17M
3
IMVT icon
Immunovant
IMVT
+$6.56M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$6.34M
5
AVR
Anteris Technologies
AVR
+$4.66M

Sector Composition

Rank Sector Weight
1 Healthcare 78.96%
2 Financials 2.75%
3 Consumer Staples 0.04%
4 Technology 0%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MOVE icon
201
Corvex Inc
MOVE
$336M
$13K ﹤0.01%
2,600
– –
CYPH
202
Cypherpunk Technologies Inc
CYPH
$75.6M
$11.9K ﹤0.01%
39,925
-71,075
-64% -$25.9K
CNTB
203
Connect Biopharma Holdings
CNTB
$132M
$10.1K ﹤0.01%
10,300
– –
CHRS icon
204
Coherus Oncology
CHRS
$227M
$7.58K ﹤0.01%
+10,366
New +$8.95K
IROHR
205
DELISTED
Iron Horse Acquisitions Corp Right
IROHR
$6.14K ﹤0.01%
12,320
-12,680
-51% -$4.79K
KVACW
206
DELISTED
Keen Vision Acquisition Corp Warrant
KVACW
$4.05K ﹤0.01%
+75,000
New +$3.84K
EMCGR
207
DELISTED
Embrace Change Acquisition Corp Rights
EMCGR
$1.5K ﹤0.01%
13,144
– –
EMCGW
208
DELISTED
Embrace Change Acquisition Corp Warrants
EMCGW
$360 ﹤0.01%
18,000
– –
AQN icon
209
Algonquin Power & Utilities
AQN
$4.46B
– –
-20,000
Closed -$103K
JBIO
210
Jade Biosciences
JBIO
$1.3B
– –
-41,750
Closed -$3.67M
BCRX icon
211
BioCryst Pharmaceuticals
BCRX
$2.28B
– –
-10,000
Closed -$75K
BNTX icon
212
BioNTech
BNTX
$23.3B
– –
-5,000
Closed -$455K
CKPT
213
DELISTED
Checkpoint Therapeutics
CKPT
– –
-305,800
Closed -$1.24M
CLRB icon
214
Cellectar Biosciences
CLRB
$20.5M
– –
-1,341
Closed -$12.7K
CRGX
215
DELISTED
CARGO Therapeutics
CRGX
– –
-341,515
Closed -$1.39M
DNTH icon
216
Dianthus Therapeutics
DNTH
$6.04B
– –
-18,285
Closed -$332K
EXAS
217
DELISTED
Exact Sciences
EXAS
– –
-5,000
Closed -$216K
IMNM icon
218
Immunome
IMNM
$2.84B
– –
-20,000
Closed -$135K
INSM icon
219
Insmed
INSM
$21.7B
– –
-6,074
Closed -$463K
IOVA icon
220
Iovance Biotherapeutics
IOVA
$1.99B
– –
-15,700
Closed -$52.3K
ISRG icon
221
Intuitive Surgical
ISRG
$132B
– –
-700
Closed -$347K
JWN
222
DELISTED
Nordstrom
JWN
– –
-12,000
Closed -$293K
KVACU
223
DELISTED
Keen Vision Acquisition Corp Units
KVACU
– –
-75,000
Closed -$842K
LYRA
224
DELISTED
LYRA THERAPEUTICS INC
LYRA
– –
-10,664
Closed -$67.3K
MREO
225
Mereo BioPharma
MREO
$49.6M
– –
-10,000
Closed -$22.5K
6 7 8
9
10

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

ADAR1 Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, ADAR1 Capital Management held 247 positions worth $652M, up 21% from $539M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

ADAR1 Capital Management deployed $93.9M of net new capital in Q2 2025, opening 47 new positions and adding to 63 existing holdings. Its largest new stake was Prothena Corp: 3,375,009 shares worth $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 78% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Roivant Sciences, an estimated $16.7M trimmed.

  • ADAR1 Capital Management's largest Q2 2025 buy was Prothena Corp: 3,375,009 shares worth $20.5M.
  • ADAR1 Capital Management added most to Keros Therapeutics in Q2 2025, an estimated $52.7M increase.
  • ADAR1 Capital Management's biggest Q2 2025 reduction was Roivant Sciences, cutting an estimated $16.7M.
  • ADAR1 Capital Management fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $6.34M.
  • ADAR1 Capital Management's ten largest holdings make up 48% of its $652M portfolio in Q2 2025.
  • ADAR1 Capital Management opened 47 new positions and closed 37 in Q2 2025.
  • ADAR1 Capital Management's portfolio value rose 21% quarter-over-quarter to $652M.

Based on ADAR1 Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.